Navigation Links
Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation

Novel Approach to Address Growing Problem of Antibiotic Resistance Published in Nature Biotechnology

VANCOUVER, British Columbia, March 26, 2007 /PRNewswire/ -- Inimex Pharmaceuticals Inc.'s product candidate IDR-1 is the first immune system trigger to cure infections without causing harmful inflammation, according to a paper published in the April 2007 issue of Nature Biotechnology.

The paper, which highlights the work of Inimex and its co-founders Dr. Bob Hancock and Dr. Brett Finlay, shows that IDR-1 protected mice against Methicillin Resistant Staphylococcus (MRSA) and Vancomycin Resistant Enterococcus (VRE) infections. With as little as one dose, IDR-1 increased the levels of key immune system fighter cells, which caused prolonged enhancement of the host immune system's response to these antibiotic-resistant pathogens. A key finding was that the product eradicated the infections without increasing the levels of pro-inflammatory cytokines that are typically present during the first stage of immunity.

"The body's immune system naturally possesses the tools to fight infections," said John North, president and chief executive officer of Inimex. "We're developing therapeutics that utilize this powerful innate response without the threat of a cytokine storm that can lead to sepsis."

Bob Hancock added: "The success of our product in controlling bacterial infection represents a novel approach at a time when antibiotic resistance is getting worse every day. With the decline of new antibiotic discovery, we desperately need new avenues of research for the treatment of super bugs."

Methicillin Resistant Staphylococcus (MRSA) and Vancomycin Resistant Enterococcus (VRE) cause infections that antibiotics can no longer treat and account for more than 90,000 deaths each year in North America alone. Inimex's goal is to develop IDR products as a new line of defense against pathogens that seek out residents of hospital and treatment centers whose immune systems are battered by age, disease or myelosuppressive medications.

The paper was published as Scott, M.G. et al. (2007) "An anti-infective peptide that selectively modulates the innate immune response" in Nature Biotechnology (April 2007, vol. 25 No. 4) and will be accessible online on March 25.

About Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first-in-class drugs that selectively trigger the body's innate defenses without causing inflammation. IDRs have major market potential for infectious diseases, cancer and inflammatory disease. Inimex's investors include BDC Venture Capital, Canadian Medical Discovery Fund, Growthworks Capital, Discovery Capital and BC Advantage Fund. For more information, visit http://www.inimexpharma.com.

    Noonan Russo

    Andrew Villani or David Schull

    212-845-4262

    

    

andrew.villani@eurorscg.com david.schull@eurorscg.com

CONTACT: Andrew Villani, , or David Schull,, both of Noonan Russo, +1-212-845-4262, forInimex Pharmaceuticals Inc. andrew.villani@eurorscg.com david.schull@eurorscg.com

Web site: http://www.inimexpharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
5. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. PromegaExpress Expands Easy Access to Products with New Cabinet
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
10. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent review ... as the number one company for hearing aids, ranking it higher ... other brands. ... Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, state-of-the-art, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):